Cargando…

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, M O, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A, Vitale, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823224/ https://www.ncbi.nlm.nih.gov/pubmed/21883896 http://dx.doi.org/10.1111/j.1582-4934.2011.01438.x

Ejemplares similares

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

IGF-I Influences Everolimus Activity in Medullary Thyroid Carcinoma
por: Gentilin, Erica, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
por: Grossrubatscher, Erika, et al.
Publicado: (2020)

Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
por: Fanciulli, Giuseppe, et al.
Publicado: (2023)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
por: Vitale, G, et al.
Publicado: (2001)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
por: Schneider, T. C., et al.
Publicado: (2015)

Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology
por: Iannaci, G., et al.
Publicado: (2013)

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
por: Caraglia, M, et al.
Publicado: (2011)

Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer
por: Marotta, Vincenzo, et al.
Publicado: (2021)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
por: Magnani, P., et al.
Publicado: (1996)

International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma
por: Xu, Bin, et al.
Publicado: (2022)

Diabetes and Cancer
por: Colao, Annamaria, et al.
Publicado: (2011)

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy
por: Colombino, M, et al.
Publicado: (2012)

Thyroid: Medullary Carcinoma
por: Somnay, Yash R., et al.
Publicado: (2013)

An Introduction to Managing Medullary Thyroid Cancer
por: de Groot, Jan Willem, et al.
Publicado: (2006)

Genetic-Clinical Profile of Subjects with Apparently Sporadic Extra-Adrenal Paragangliomas
por: Ramundo, Valeria, et al.
Publicado: (2012)

Hypercalcitoninemia is not Pathognomonic of Medullary Thyroid Carcinoma
por: Toledo, Sergio PA, et al.
Publicado: (2009)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
por: Marra, Monica, et al.
Publicado: (2011)

New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma
por: Lukyanov, Sergei A., et al.
Publicado: (2023)

Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast
por: Kanteti, Archana P., et al.
Publicado: (2020)

Medullary carcinoma of the thyroid gland.
por: Russell, C.
Publicado: (1980)

Diagnosis of medullary thyroid cancer
por: Marchisotta, Stefania, et al.
Publicado: (2009)

Medullary carcinoma of the thyroid: an update
por: Alevizaki, Maria
Publicado: (2013)

Pediatric Medullary Thyroid Carcinoma
por: Starenki, Dmytro, et al.
Publicado: (2015)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Everolimus in Anaplastic Thyroid Cancer: A Case Series
por: Harris, Ethan J., et al.
Publicado: (2019)

How I treat medullary thyroid cancer
por: Kiesewetter, B., et al.
Publicado: (2021)

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines
por: Dicitore, A., et al.
Publicado: (2021)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

Kinase inhibitors for advanced medullary thyroid carcinoma
por: Schlumberger, Martin, et al.
Publicado: (2012)

Medullary Thyroid Cancer: It is a pain in the neck?
por: Guerrero, Marlon A., et al.
Publicado: (2011)

ACTH-secreting medullary thyroid cancer: a case series
por: Wijewardene, Ayanthi A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dsgpn7bbp9vdu8hvv5pqhp1387